Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ?

Completed

• Conditions: Is Targeted Therapy Increasing Survival Inoperable Nonsmall Cell Lung Cancer With Spinal Metastasis ?
• Interventions: Drug: Gefitinib

• Registration Number: NCT02740894
• Lead Sponsor: Taipei Veterans General Hospital, Taiwan

Brief Summary

Not significantly increased survival in T/T

Detailed Description

Not available

Study Timeline

• Study Start: 2016-02
• Status Verified: 2016-04
• Primary Completion: 2016-04
• Study Completion: 2016-04
• Study First Submitted: 2016-04-05
• Study First Submitted QC: 2016-04-12
• Last Update Submitted: 2016-04-12
• Study First Posted: 2016-04-15
• Last Update Posted: 2016-04-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• NSCLC with spinal metastasis

Exclusion Criteria

• brain metastasis and expected survival < 3 months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
targeted therapy	Gefitinib	according to national healthy policy, targeted therapy is the optional therapy
traditional chemotherapy	Gefitinib	according to national healthy policy, chemotherapy is the first line treatment.

Primary Outcome Measures

Name	Time	Method
Survival and neurologic outcome of 60 participants receiving targeted therapy for nonsmall cell lung cancer with spinal metastaasis. Neurological outcome by Frankel grading and ambulation status.	postoperation to mortality, up to 2 year